Highlights

  • NVO rose nearly 3% on December 05, 2025, outpacing the S&P 500.
  • New bipartisan bill seeks tighter limits on compounded GLP-1 medications.
  • Lawmakers cite safety concerns and pressure on FDA-approved treatments.

Novo Nordisk (NYSE:NVO) recorded a gain of nearly 3% on December 12, 2025, to close at USD 50.29. The advance followed news of a legislative effort aimed at restricting the compounding of certain approved drugs, including GLP-1 treatments. The company is widely known for its weight-loss drug Wegovy.

Bipartisan Legislative Effort

A new bill proposed by U.S. Representatives Rudy Yakym and Andre Carson seeks to tighten rules around the production of FDA-approved drugs by compounding pharmacies. These pharmacies can produce customized medications, but the bill aims to limit the compounding of FDA-approved treatments at scale.

GLP-1 drugs fall under the scope of the proposal. This includes Wegovy from Novo Nordisk and Zepbound from Eli Lilly. The compounding of GLP-1 medications has created added pressure for companies behind these branded drugs. The draft bill highlights concerns that some entities may be using compounding channels to manufacture unapproved versions that compete with regulated products.

Statement From Lawmakers

In a joint release, Yakym and Carson stated:
"While compounding serves important individualized medical needs, some entities are exploiting it to illegally manufacture and sell untested, unapproved drugs at scale."

They further noted:
"These products endanger patients, undermine trust in FDA-approved medicines, and weaken incentives to develop new treatments."

Outlook for the Proposed Bill

The bill’s progress remains uncertain. Congress is approaching its holiday recess and continues to focus on broader national issues. It may take time before the proposal moves through committee reviews or receives wider debate.

However, the development signals a renewed policy focus on compounded GLP-1 medications. Companies with approved obesity drugs or active pipelines in this category are monitoring the situation. The legislative move adds a new dimension to the ongoing discussion around drug safety, regulatory oversight, and the commercialization of high-demand treatments.